Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100528 · ClinicalTrials.gov registry record · Phase 2
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
A Phase 2 study of Iris Melanoma and Ciliary Body and Choroid Melanoma, Medium/Large Size, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01100528 is a Phase 2 study of Iris Melanoma and Ciliary Body and Choroid Melanoma, Medium/Large Size that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01100528, a Phase 2 study of Iris Melanoma and Ciliary Body and Choroid Melanoma, Medium/Large Size, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving interferon alfa-2b together with dacarbazine may be an effective treatment for primary uveal melanoma. PURPOSE: This phase II trial is studying how well giving dacarbazine together with recombinant interferon alfa-2b works in treating patients with primary uveal melanoma with genetic imbalance.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG dacarbazine
- BIOLOGICAL recombinant interferon alfa-2b
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-11-11 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100528
The ClinicalTrials.gov registry entry for NCT01100528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Iris Melanoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01100528 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01100528 about?
NCT01100528 is a clinical study titled "Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance". RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving interferon alfa-2b together with da...
What is the current status of trial NCT01100528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2009-11-11. Estimated completion is 2017-12-14.
What conditions does trial NCT01100528 study?
This clinical trial studies the following conditions: Iris Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Recurrent Intraocular Melanoma.
What interventions are being tested in trial NCT01100528?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dacarbazine (DRUG), recombinant interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT01100528?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01100528 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iris Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.